Prescription change from cinacalcet hydrochloride to evocalcet in hemodialysis patients

Prescription change from cinacalcet hydrochloride to evocalcet in hemodialysis patients with secondary hyperparathyroidism - Switching from cinacalcet hydrochloride to evocalcet in hemodialysis patients with SHPT

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000036702

Enrollment

150

Registered

2019-05-10

Start date

2018-09-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hemodialysis patients with secondary hyperparathyroidism

Interventions

Prescription change from cinacalcet hydrochloride (usual dose) to evocalcet (1 mg/day) and followed for 12 months. Questionnaire on GI symptoms and medication adherence.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Chronic hemodialysis patients treated with cinacalcet hydrochloride

Exclusion criteria

Exclusion criteria: Patients not treated with cinacalcet hydrochloride Patients without informed consent

Design outcomes

Primary

Measure	Time frame
Serum parathyroid hormone (PTH) levels for 12 months after the switching.	—

Secondary

Measure	Time frame
Evocalcet dose Serum corrected calcium levels Serum phosphate levels Serum alkaline phosphatase levels Questionnaire on GI symptoms and medication adherence Concomitant medication	—

Countries

Japan

Contacts

Public ContactNobuo Nagano

Hidaka Hospital, Hidaka-kai Kidney Disease and Dialysis Center

n_nagano@hidaka-kai.com027-362-6201

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026